Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD19 x BCMA SIR-T
- Development stage
- Preclinical
- Lead developer
- Angeles Therapeutics
- Modality
- Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD19 x BCMA SIR-T is an investigational dual-targeting cell therapy being developed by Angeles Therapeutics for the treatment of B-cell malignancies and plasma cell disorders. The therapy utilizes the company's proprietary Synthetic Immune Receptor T-cell (SIR-T) platform, which engineers T-cells to express synthetic receptors designed to mimic the natural T-cell receptor (TCR) signaling architecture. By simultaneously targeting B-lymphocyte antigen CD19 and B-cell maturation antigen (BCMA), this candidate aims to reduce the risk of antigen escape and improve therapeutic durability in patients with heterogeneous hematologic cancers. The program is currently in the IND-enabling stage of development.
- Other names
- CD19/BCMA SIR-TCD19 x BCMA Synthetic Immune Receptor T-cell therapyCD-19 x BCMA Synthetic Immune Receptor T-cell therapyCD 19 x BCMA Synthetic Immune Receptor T-cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CD19 x BCMA SIR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD19 x BCMA SIR-T.